$3.35
2.62% yesterday
Nasdaq, Nov 25, 10:07 pm CET
ISIN
US46333X1081
Symbol
IRWD

Ironwood Pharmaceuticals Stock price

$3.35
-0.61 15.40% 1M
-2.60 43.70% 6M
-8.09 70.72% YTD
-6.25 65.10% 1Y
-8.23 71.07% 3Y
-8.85 72.54% 5Y
-8.21 71.02% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.09 2.62%
ISIN
US46333X1081
Symbol
IRWD
Sector
Industry

Key metrics

Market capitalization $536.09m
Enterprise Value $1.06b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 8.58
EV/Sales (TTM) EV/Sales 2.81
P/S ratio (TTM) P/S ratio 1.42
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -12.48%
Revenue (TTM) Revenue $378.42m
EBIT (operating result TTM) EBIT $117.06m
Free Cash Flow (TTM) Free Cash Flow $123.82m
Cash position $88.21m
EPS (TTM) EPS $-0.02
P/E forward 33.50
P/S forward 1.52
EV/Sales forward 3.01
Short interest 13.23%
Show more

Is Ironwood Pharmaceuticals a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Ironwood Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Ironwood Pharmaceuticals forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Ironwood Pharmaceuticals forecast:

Buy
83%
Hold
17%

Financial data from Ironwood Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
378 378
12% 12%
100%
- Direct Costs 2.04 2.04
46% 46%
1%
376 376
13% 13%
99%
- Selling and Administrative Expenses 138 138
6% 6%
36%
- Research and Development Expense 120 120
34% 34%
32%
119 119
39% 39%
31%
- Depreciation and Amortization 2.04 2.04
46% 46%
1%
EBIT (Operating Income) EBIT 117 117
39% 39%
31%
Net Profit -2.46 -2.46
100% 100%
-1%

In millions USD.

Don't miss a Thing! We will send you all news about Ironwood Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ironwood Pharmaceuticals Stock News

Neutral
Business Wire
13 days ago
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 7:30 a.m. GT at the Waldorf Hilton in London. A live webcast of Ironwood's fireside chat will be accessible through the I...
Neutral
Seeking Alpha
18 days ago
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q3 2024 Earnings Call Transcript November 7, 2024 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Operating Officer & Chief Financial Officer Conference Call Participants Amy Li - Jefferies David Amsellem - Piper Sandler Jas...
Neutral
Business Wire
19 days ago
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. “LINZESS continued to deliver robust prescription demand growth in the third quarter,” said Tom McCourt, chief executive officer of Ironwood Pharmaceuticals. “LINZESS extended units and new-to-brand prescriptions ...
More Ironwood Pharmaceuticals News

Company Profile

Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.

Head office United States
CEO Thomas McCourt
Employees 267
Founded 1998
Website www.ironwoodpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today